NR AHEP
AU Lemstra,A.W.; van Meegen,M.T.; Vreyling,J.P.; Meijerink,P.H.; Jansen,G.H.; Bulk,S.; Baas,F.; van Gool,W.A.
TI 14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: a prospective study in 112 patients.
QU Neurology 2000 Aug 22; 55(4): 514-6
PT clinical trial; journal article
AB OBJECTIVE: To study the sensitivity and specificity of 14-3-3 testing in a prospective series of patients suspected of having Creutzfeldt-Jakob disease (CJD). BACKGROUND: The 14-3-3 protein immunoassay on CSF has favorable test characteristics as a premortem diagnostic tool in CJD. However, the 14-3-3 protein is a normal cellular protein expressed in various tissues, and its presence in CSF reflects extensive destruction of brain tissue as in CJD, but also in ischemic stroke and meningoencephalitis. METHODS: 14-3-3 was tested in the CSF of a prospective series of 110 consecutive patients suspected of having CJD. RESULTS: The sensitivity was 97% and the specificity was 87% in this series. False-positive results were mainly caused by stroke and meningoencephalitis. CONCLUSION: The 14-3-3 protein is a highly sensitive and specific marker for CJD when used in the appropriate clinical context.
MH Adult; Aged; Astrocytoma/cerebrospinal fluid/*diagnosis; Biological Markers/cerebrospinal fluid; Brain Diseases/cerebrospinal fluid/diagnosis; Brain Neoplasms/cerebrospinal fluid/*diagnosis; Cerebrospinal Fluid/chemistry; Creutzfeldt-Jakob Syndrome/cerebrospinal fluid/*diagnosis; Diagnosis, Differential; False Positive Reactions; Female; Human; Lymphoma/cerebrospinal fluid/*diagnosis; Male; Middle Age; Predictive Value of Tests; Prospective Studies; Proteins/*analysis; Sensitivity and Specificity
AD Department of Neurology, Academic Medical Center, University of Amsterdam, The Netherlands. a.w.lemstra@amc.uva.nl
SP englisch
PO USA